{"filing":{"accession_number":"0001104659-26-100532","cik":"0001720893","ticker":"BTAI","company_name":"BioXcel Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-24","primary_document":"tm2623945d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926100532/tm2623945d1_8k.htm"},"events":[{"id":29317,"run_id":26833,"accession_number":"0001104659-26-100532","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"BioXcel entered into the Fourteenth Amendment to its Credit Agreement on August 24, 2026, under which Lenders made additional loans of $1,250,000 in principal. While the amendment also includes covenant modifications (reduced minimum liquidity to $250,000 and a requirement to enter into capital solutions transactions by August 31, 2026), the core disclosed action is the creation of a new direct financial obligation—the Amendment No. 14 Term Loans. The 20% upfront fee and the tight liquidity covenant suggest financial stress, but the primary event is debt issuance. The covenant modifications and capital-solutions deadline hint at covenant_breach or going_concern risk, but the filing centers on the new loan facility itself.","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31560,"accession_number":"0001104659-26-100532","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"BioXcel entered into the Fourteenth Amendment to its Credit Agreement on August 24, 2026, under which Lenders made additional loans of $1,250,000 in principal. While the amendment also includes covenant modifications (reduced minimum liquidity to $250,000 and a requirement to enter into capital solutions transactions by August 31, 2026), the core disclosed action is the creation of a new direct financial obligation—the Amendment No. 14 Term Loans. The 20% upfront fee and the tight liquidity covenant suggest financial stress, but the primary event is debt issuance. The covenant modifications and capital-solutions deadline hint at covenant_breach or going_concern risk, but the filing centers on the new loan facility itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T11:16:42.427661+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31560,"accession_number":"0001104659-26-100532","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"BioXcel entered into the Fourteenth Amendment to its Credit Agreement on August 24, 2026, under which Lenders made additional loans of $1,250,000 in principal. While the amendment also includes covenant modifications (reduced minimum liquidity to $250,000 and a requirement to enter into capital solutions transactions by August 31, 2026), the core disclosed action is the creation of a new direct financial obligation—the Amendment No. 14 Term Loans. The 20% upfront fee and the tight liquidity covenant suggest financial stress, but the primary event is debt issuance. The covenant modifications and capital-solutions deadline hint at covenant_breach or going_concern risk, but the filing centers on the new loan facility itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T11:16:42.427661+00:00","company_name":"BioXcel Therapeutics, Inc.","ticker":"BTAI","filing_date":"2026-08-25"}]}